EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity

Des C Jones, Lorraine Irving, Rebecca Dudley, Seraina Blümli, Marcin Wolny, Elisavet I Chatzopoulou, Stacy Pryts, Shreya Ahuja, D Gareth Rees, Alan M Sandercock, Saravanan Rajan, Reena Varkey und 12 weitere

Journal for ImmunoTherapy of Cancer · 2025-04 · 13 (4) · e010012

DOI: 10.1136/jitc-2024-010012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 17.04.2025. Verfasst von Des C Jones und 23 weiteren Autor:innen. Beteiligte Einrichtung: ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK desjones@hotmail.com. Hauptthemen laut MEDLINE: Receptors, Immunologic, Macrophages, T-Lymphocytes, Leukocyte Immunoglobulin-like Receptor B1. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors have revolutionized the treatment of solid tumors, enhancing clinical outcomes by releasing T cells from inhibitory effects of receptors like programmed cell death protein 1 (PD-1). Despite these advancements, achieving durable antitumor responses remains challenging, often due to additional immunosuppressive mechanisms within the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) contribute significantly to the immunosuppressive TME and play a pivotal role in shaping T cell-mediated antitumor responses. Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2), expressed on myeloid cells, including TAMs, is an inhibitory receptor, which contributes to macrophage-mediated immunosuppression. In this study, we present AZD2796, a high-affinity anti-LILRB2 antibody designed to repolarize TAMs from an immunosuppressive to a proinflammatory phenotype.

Methods

Anti-LILRB2 antibodies were identified using single-B-cell encapsulation Immune Replica technology. The ability of AZD2796 to enhance proinflammatory responses from macrophages treated with CD40 ligand or lipopolysaccharide was assessed using a macrophage stimulation assay. A tumor cell/macrophage/T cell co-culture assay was developed to evaluate the effect of AZD2796, as a single agent and in combination with an anti-PD-1 antibody, on the cytolytic activity of antigen-specific T cells. In vivo assessments were then carried out to determine the ability of AZD2796 to alter tumor growth rate in mice humanized with CD34 hematopoietic stem cells.

Results

In preclinical assessments, AZD2796 skewed macrophage differentiation away from an immunosuppressive phenotype and enhanced the proinflammatory function of macrophages. AZD2796 significantly increased the anti-tumor response of T cells following PD-1 checkpoint blockade, while AZD2796 monotherapy reduced tumor growth in humanized mouse models.

Conclusions

These findings support the potential of AZD2796 as an anti-cancer therapy, with the ability to synergize with T-cell-based therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicMacrophagesT-LymphocytesLeukocyte Immunoglobulin-like Receptor B1AnimalsMiceHumansFemaleTumor MicroenvironmentCell Line, TumorMembrane Glycoproteins

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapyMacrophageTumor infiltrating lymphocyte - TIL

Substanzen

Receptors, ImmunologicLILRB2 protein, humanLeukocyte Immunoglobulin-like Receptor B1Membrane Glycoproteins

Autor:innen und Institutionen

  • ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK desjones@hotmail.com.
  • Immunocore Ltd, Abingdon, UK.
  • Biologics Engineering, AstraZeneca, Cambridge, UK.
  • ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.
  • ICC, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Dynamic Omics, CGR, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.

Förderung

  • AstraZeneca

Zitieren

APA

Jones, D. C., Irving, L., Dudley, R., Blümli, S., Wolny, M., Chatzopoulou, E. I., Pryts, S., Ahuja, S., Rees, D. G., Sandercock, A. M., Rajan, S., Varkey, R., Kierny, M., Kayserian, A., Mulgrew, K., Bowyer, G., Songvilay, S., Bienkowska, K., Glover, M. S., …, & Cobbold, M. (2025). LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity. Journal for ImmunoTherapy of Cancer, 13(4), e010012. https://doi.org/10.1136/jitc-2024-010012

Vancouver

Jones DC, Irving L, Dudley R, Blümli S, Wolny M, Chatzopoulou EI, et al. LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity. Journal for ImmunoTherapy of Cancer. 2025;13(4):e010012. doi:10.1136/jitc-2024-010012

BibTeX
@article{Jones2025,
  author = {Jones, Des C and Irving, Lorraine and Dudley, Rebecca and Blümli, Seraina and Wolny, Marcin and Chatzopoulou, Elisavet I and Pryts, Stacy and Ahuja, Shreya and Rees, D Gareth and Sandercock, Alan M and Rajan, Saravanan and Varkey, Reena and Kierny, Michael and Kayserian, Andrew and Mulgrew, Kathy and Bowyer, Georgina and Songvilay, Saly and Bienkowska, Kamila and Glover, Matthew S and Hess, Sonja and Dovedi, Simon J and Wilkinson, Robert W and Arnaldez, Fernanda and Cobbold, Mark},
  title = {LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {e010012},
  doi = {10.1136/jitc-2024-010012}
}
Kostenlos starten →